Immunity conferred by T-cells-based vaccine could last longer

Synopsis The researchers from Pennsylvania State University, US, said that such a vaccine may provide long-lasting immunity against future emerging variants and could also be used as a model for other seasonal viral diseases like the flu. AP Immunity conferred by T-cells-based vaccine could last longer Researchers have demonstrated the effectiveness of an artificial intelligence-generated vaccine, focusing on T-cells, in mice. The researchers from Pennsylvania State University , US, said that such a vaccine may provide long-lasting immunity against future emerging variants and could also be used as a model for other seasonal viral diseases like the flu.

They said that the current COVID-19 vaccines, designed to trigger an antibody response to the SARS-CoV-2 spike protein, were vulnerable to mutations that could make the vaccine less effective over time. They partnered with Evaxion Biotech , a biotechnology firm based in Denmark , on the study, which is published in the journal Frontiers in Immunology. Upon being challenged with a lethal dose of SARS-CoV-2, the researchers found that 87.

5 per cent of the mice vaccinated with the T-cell-based vaccine survived while only one of the control-group mice survived. All the vaccinated mice that survived were also found to have cleared the infection within 14 days post-challenge. “To our knowledge, this study is the first to show in vivo [in a living organism] protection against severe COVID-19 by an AI-designed T-cell vaccine,” said Girish Kirimanjeswara , associate professor of veterinary and biomedical sciences, Penn State .

“Our vaccine was extremely effective at preventing severe COVID-19 in mice, and it can be easily scaled up to start testing it in humans, as well,” said Kirimanjeswara. According to Kirimanjeswara , the spike protein of the SARS-CoV-2 virus is under heavy selection pressure, which can result in mutations that drive the emergence of new variants. “This means that [mRNA] vaccine manufacturers will have to keep creating new vaccines that target new variants, and people have to keep getting these new vaccines,” he said.

Instead of targeting the constantly mutating spike protein, the team at Evaxion Biotech designed a vaccine that included 17 epitopes, or sites on antigen molecule, from various proteins of SARS-CoV-2 that are recognized by the immune system. The researchers said that these epitopes elicit an immune response from a broad selection of T cells, ensuring a sustained coverage of future variants. One advantage of this, Kirimanjeswara said, was that the virus would have to undergo too many mutations to be able to escape this T-cell-mediated immunity.

The other one, he said, was that repeated booster doses would not be needed owing to the immunity conferred by T-cells, which is usually long-lasting. He said that it was harder and more time-consuming to produce a T-cell-based vaccine than an antibody-based one. “Given the urgency with which we needed a vaccine to address the COVID-19 pandemic, it makes sense that vaccine manufacturers created an antibody-based vaccine.

Now that the urgency has passed, a second-generation T-cell-based vaccine could be more effective and last longer,” he said. The study’s co-author Anders Bundgaard Sorensen , project director, Evaxion Biotech, said that this vaccine used multiple types of artificial intelligence in a platform called RAVEN ( Rapidly Adaptive Viral rEspoNse) to predict ideal targets for vaccines. “RAVEN is really adaptable,” Sorensen said.

“We don’t have to wait for a new strain of a virus to arrive to develop a vaccine. Instead, we can predict what will be needed in advance. ” Sorensen noted, “It’s much easier to get broad coverage with a T-cell vaccine, as we can include multiple epitopes targeting different proteins.

” Sorensen said that because RAVEN could predict what was needed, it could also be used to develop better influenza vaccines, in addition to producing better COVID-19 vaccines. Don’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp. click here! Saturday, 15 Apr, 2023 Experience Your Economic Times Newspaper, The Digital Way! Read Complete Print Edition » Front Page Pure Politics Companies Markets More CPPIB, OMERS on Road to ₹4.

3kcr Infusion in IndInfravit The Canada Pension Plan Investment Board (CPPIB) and the Ontario Municipal Employees Retirement System (OMERS) are planning to invest more than ₹4,300 crore ($526 million) in IndInfravit, an infrastructure investment trust (InvIT) that owns and operates Indian road assets and is majority owned by the two investors, said two persons aware of the development. Govt Working on Fact-Check Unit Contours: IT MoS The government is considering multiple proposals for the design of its proposed fact-check unit, which will be mandated to ascertain the veracity of government-related information online, minister of state for electronics and information technology Rajeev Chandrasekhar said on Friday. VoVL Lenders OK Sale of Oil Basins to 2 Brazil Firms, with a Rider Lenders to VoVL, the oil and gas exploration company of Videocon Industries, Thursday approved a conditional sale of two oil basins to Eneva S A and one to PetroRio, said people aware of the development.

Read More News on pennsylvania state university covid 19 evaxion biotech sorensen penn state rapidly adaptive viral girish kirimanjeswara kirimanjeswara anders bundgaard sorensen denmark (Catch all the Business News , Breaking News Events and Latest News Updates on The Economic Times . ) Download The Economic Times News App to get Daily Market Updates & Live Business News. .

. . more less ETPrime stories of the day Under the lens In the top-end, pro space, digital cameras find a safe niche 5 mins read Green tech Net-zero in mind, how Project Aalingana is making Tata companies embrace sustainable transformation 12 mins read OTT What’s common between Yash Chopra, Facebook, Google and RIL? Their romance for risk.

10 mins read Subscribe to ETPrime.